口服版司美格鲁肽国内获批上市，临床结果显示，可有效降糖、减肥

2024-02-06

2024年1月26日，国家药监局官网显示，诺和诺德开发的司美格鲁肽片获批上市，用于治疗2型糖尿病。这也是国内首个获批上市的口服GLP-1受体激动剂。此前，注射版司美格鲁肽已于2021年在国内获批上市，同样用于治疗2型糖尿病。2023年3月24日，诺和诺德发布了口服版司美格鲁肽在治疗2型糖尿病的3b期临床试验的数据。

Pre: Semaglutide has a real rival! Lilly's strongest weight-loss drug, tilpotide is approved by the FDA

Next: The oral version of Semaglutide was approved for domestic market, and clinical results showed that it can effectively reduce blood sugar and lose weight

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.

Copyright © 2010-2024 Fluoropharm Co.,Ltd. All rights reserved.

浙ICP备2023037538号-1